ArticleScientific reports2018

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Thomas S Worst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.